This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beinart, S. C. Articles by Weintraub, W. S. Search for Related Content PubMed PubMed Citation Articles by Beinart, S. C. Articles by Weintraub, W. S.

Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention

Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial

Sean C. Beinart, MD, MSc^_*, Paul Kolm, PhD^_*, Emir Veledar, PhD^_*, Zefeng Zhang, MD, PhD^_*, Elizabeth M. Mahoney, ScD, Olivier Bouin, MD, Sylvie Gabriel, MD, Joseph Jackson, PhD, Roland Chen, MD, Jaime Caro, MD^||, Steven Steinhubl, MD^¶, Eric Topol, MD^# and William S. Weintraub, MD^_*,_*

^_* Emory University, Atlanta, Georgia
New England Research Institutes, Watertown, Massachusetts
Sanofi-Aventis, Paris, France
Bristol-Myers Squibb, Princeton, New Jersey
^|| Caro Research Institute, Concord, Massachusetts
^¶ University of Kentucky, Lexington, Kentucky
^# Cleveland Clinic, Cleveland, Ohio

View larger version (47K): [in a new window]   Figure 1 Scatterplot of the joint distribution of bootstrap estimates of cost and effectiveness differences based on Blended costs for Framingham (left) and Saskatchewan (right) life expectancy estimates. The line extending through the origin (0.0) is a hypothetical cost-effectiveness threshold of $50,000 per life-year gained.

View larger version (29K): [in a new window]   Figure 2 Cost-effectiveness acceptability curves based on Medicare/MEDSTAT costs for Framingham and Saskatchewan life expectancy estimates. CE = cost effectiveness.